Abbarna A. Cumaraswamy

Immunology and Microbiology · Life Sciences

7h-index466citations21works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(8), Cytokine Signaling Pathways and Interactions(7), Chronic Myeloid Leukemia Treatments(6), Chronic Lymphocytic Leukemia Research(3), Lymphoma Diagnosis and Treatment(2)

Publications21 total

Supplementary Figures S1 - S8 from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
Data from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
Supplementary Figures S1 - S8 from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
Data from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
Supplementary Methods, Figure Legends from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
Supplementary Methods, Figure Legends from STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
2023Open Access
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
Haematologica·2019· 43 citedOpen Access
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
Leukemia·2018· 147 citedOpen Access
Abstract 1184: Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases
Cancer Research·2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
Haematologica·2017· 39 citedOpen Access
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
Cancer Discovery·2016· 144 cited
ID: 66
Cytokine·2015
The Design Development of Small Molecule Inhibitors Targeting Unregulated Transcription Factors in Acute Myeloid Leukemia
TSpace (University of Toronto)·2015
285 A nanomolar-potency small molecule inhibitor of the STAT5 protein
European Journal of Cancer·2014· 1 citedOpen Access
Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein
ACS Medicinal Chemistry Letters·2014· 61 citedOpen Access
Progress towards direct inhibitors of Stat5 protein
Hormone Molecular Biology and Clinical Investigation·2012· 7 cited
Verdazyl Radicals as Substrates for Organic Synthesis: The Synthesis and Characterization of [12]‐, [13]‐, and [21]‐Paraheteraphanes
European Journal of Organic Chemistry·2012· 6 cited
CCDC 862211: Experimental Crystal Structure Determination
The Cambridge Structural Database·2012Open Access
CCDC 862210: Experimental Crystal Structure Determination
The Cambridge Structural Database·2012Open Access
Abstract B224: Structure-based drug design of signal transducers and activator of transcription 5 inhibitors.
Molecular Cancer Therapeutics·2011
page 1 of 2Next →

Frequent Co-authors

Patrick T. Gunning(17), Richard Moriggl(12), Mathias Müller(8), Veronika Sexl(8), Dagmar Gotthardt(7), Eva Maria Putz(7), Eva Grundschober(7), Elisabeth Straka(7), Petra Kudweis(7), Gerwin Heller(7), Zsuzsanna Bagó-Horváth(7), Agnieszka Witalisz‐Siepracka(7), Birgit Strobl(7), Christian Stockmann(7), Michaela Prchal-Murphy(6), Peter Valent(5), Bettina Wingelhofer(4), Stefan Kubicek(4), Barbara Maurer(3), Elizabeth Heyes(3)